Kornimate/medical-research-clean huggingface dataset:
a postmarket clinical trial for excrossal stent in cad patients with 3-month dapt or 12-month dapt

Conditions: Coronary Artery Disease

Summary: 1. prospective, randomized, multicenter clinical study 2. this is a post-marketing clinical study to evaluate whether it will affect the safety event when it is used in different treatment ways. adopting non - inferiority design, 2700 cases were enrolled. 3. edc system (ecrf electronic data collection system) 4. follow-up points: 30 days,3 months, 12 months, 24 months, 36 months, 48 months and 60 months after the operation;

1. subjects are eligible for coronary intervention 2. the lesion needs to be pre-expanded or special circumstances should be carefully considered according to the clinical manifestations 3. the selection of target vessel is based on the criteria of a diameter between 2.25mm and 4.0mm 4. if a stent needs to be placed at the target vessel, it is recommended that there be at least 2mm overlap between the stents; if the stent expansion is not sufficient, post-dilatation treatment is required.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years and ≤75 years; 2. de novo coronary artery primary lesions; 3. stable angina pectoris; 4. patients with coronary artery disease with similar symptoms of myocardial ischemia or angina; 5. suitable for pci indication and suitable for the implant of excrossal stents. 6. able to understand the purpose of the study, voluntarily participate and sign the informed consent form, and willing to accept the clinical follow-up; imaging criteria the target lesion length≤ 60mm；visual reference diameter of the vessel is 2.25-4.0mm; exclusion criteria: 1. patients with acute myocardial infarction (ami) within 7 days; non-st elevated acs patients 2. those who implanted any stent before; 3. left ventricular ejection score(lvef) 30 % 4. patients with bleeding tendency or anticoagulation treatment contraindications and/or pci contraindications or coagulopathy; 5. there are other diseases such as cancer, malignant tumor, congestive heart failure, organ transplant, or candidate) or has a history of abuse (alcohol, cocaine, heroin, etc.), plan adherence is poor, or the life expectancy of less than 1 year; 6. it is estimated that elective surgery patients within 12 months; 7. other coronary lesions requiring staged intervention; 8. if there are branches of blood vessels that need to be treated, the diameter of blood vessels ≥ 2.5 mm; 9. the subject's compliance or the researcher's judgment was not suitable for the participants in the study; 10. pregnant or lactating persons; imaging criteria 1. left main disease, transplanted vessel lesions, stent restenosis; 2. the balloon cannot be predilated or/or the severe calcification lesion of rotatory failure; 3. the distortion of the stent is difficult to pass;
intra-arterial thrombolysis for severe recent central retinal vein occlusion

Conditions: Central Retinal Vein Occlusion

Summary: central retinal vein occlusion (crvo) is a common cause of vision loss, typically affecting individuals during the fifth through seventh decade of life. eyes with severe crvo have a poor visual prognosis because current treatments address only secondary complications of crvo without treating its cause. intra-ophthalmic artery injection of a small dose of t-pa (clot busting medicine), also called intra-ophthalmic artery thrombolysis, may reopen the central retinal vein-and address the cause of the disease- without exposing the subject to the risks of systemic thrombolysis. our project aims to evaluate the safety and efficacy of intra-ophthalmic artery thrombolysis in subjects with crvo.

1. study hypothesis: injection of t-pa, a thrombolytic drug (clot busting medicine)into the ophthalmic artery (the blood vessel feeding the eye), in patients with recent severe central retinal vein occlusion, may reopen the central retinal vein and improve retinal blood flow, which may in turn improve visual acuity and prevent the long-term complications of the disease. 2. experimental intervention: an outpatient procedure during which the ophthalmic artery is selective catheterized (with a small plastic tube called a microcatheter introduced from the artery of the leg) and infused with t-pa during two hours.

Eligibility criteria:
inclusion criteria: * severe crvo diagnosed on * presence of relative afferent papillary defect (rapd) * or visual acuity of 20/200 or worse * symptom onset within 2 weeks * age \> 18 years old * patient is able and willing to give informed consent exclusion criteria: * futile intervention: no light perception, absence of perfusion on fluorescein angiography. * contra-indication to thrombolysis: active or recent (1 month) internal bleeding, cerebrovascular accident, major organ surgery, major trauma; intracranial neoplasm or vascular malformation, known bleeding diathesis, severe uncontrolled arterial hypertension, pregnancy (women of childbearing age must have a negative serum pregnancy test), or any other condition which in the opinion of the investigators would preclude the use of thrombolytic agents. * high-risk catheterization: history of stroke or tia; carotid bruit or known carotid occlusive disease; any cardiovascular condition that in the opinion of the investigators may increase the risk of catheterization of the ophthalmic artery. * ocular criteria: intraocular neovascularization (secondary to any etiology), vitreous hemorrhage, inflammatory eye disease, any condition that precludes fundus photography or fluorescein angiography.

Keywords: central retinal vein occlusion macular edema vision loss relative afferent papillary defect
application of ultrasound artificial intelligence and elastography in differential diagnosis of thyroid nodules

Conditions: Thyroid Nodule

Summary: the application of computer-aided diagnosis (cad) technology "s-detecttm" enables qualitative and quantitative automated analysis of ultrasound images to obtain objective, repeatable and more accurate diagnostic results. the elastic contrast factor (eci) technique, unlike conventional strain-elastic imaging techniques, can evaluate the elastic distribution in the region of interest. the purpose of the study was to evaluate the differential diagnosis value of ultrasound s-detecttm technology for benign and malignant thyroid nodules and evaluate the consistency of ultrasound s-detecttm technology and sonographer in the differential diagnosis of thyroid nodules and explore the differential diagnosis value of samsung ultrasound eci technology for benign and malignant thyroid nodules.

thyroid nodules are one of the most common nodular lesions in adults, and their incidence is increasing. clinical studies have found that about 10%-15% of adults have thyroid nodules, most of which are benign nodules, only 7% of thyroid nodules tend to be malignant, but if not treated promptly, 5% of patients will still from benign to malignant. the incidence of thyroid cancer increases with age. according to the national cancer research center, about 64,300 new cases of thyroid cancer occurred in the world in 2016, and about 1,980 died of thyroid cancer. timely and accurate detection of thyroid nodules and differentiation of benign and malignant are important for improving clinical treatment and improving patient prognosis. s-detect technology is a computer-aided (cad) system recently developed by samsung medical center for thyroid ultrasound to assist in morphological analysis based on the thyroid imaging reporting and data system (ti-rads) description and final assessment.this provides a new way to identify the benign and malignant thyroid nodules. the eci technique, unlike conventional strain-elastic imaging technology, performs an elastic analysis of the entire two-dimensional image. moreover, when measuring the elastic ratio, it is only necessary to place a region of interest (roi) at the nodule. compared with the average elasticity of the surrounding area, it is more reflective of the elastic ratio of the mass to the surrounding tissue.

Eligibility criteria:
inclusion criteria: 1. had thyroid lesions detected by ultrasound 2. age 18 or older 3. upcoming fnab or surgery 4. signing informed consent exclusion criteria: 1. patients who had received a biopsy of thyroid lesion before the ultrasound examination 2. can not cooperate with the test operation 3. patients who were pregnant or lactating 4. patients who were undergoing neoadjuvant treatment.

Keywords: artificial intelligence; ultrasound;thyroid nodule; eci
fine-needle biopsy combined with macroscopic on-site evaluation for diagnosis of solid pancreatic lesions

Conditions: Pancreatic Diseases

Summary: the goal of this clinical trial is to compare the diagnostic efficacy, core tissue acquisition ability, number of punctures and puncture time of macroscopic on-site evaluation (mose) and two punctures alone in endoscopic ultrasound guided fine-needle biopsy (eus-fnb) for solid pancreatic lesions. the main questions it aims to answer is: whether the diagnostic accuracy of eus-fnb performed with two needle passes is not inferior to that of mose. participants with solid pancreatic lesions who needs histological diagnosis will receive eus-fnb using 22g franseen. in group 1, the macroscopically visible core (mvc) of the specimen was assessed. if the mvc of the sample obtained from the first needle was ≥10mm, the tissue strip was placed in bottle a and fixed with formalin. a second needle was then used to obtain another tissue strip, which was directly placed into bottle b containing formalin. however, if the mvc of the first needle sample was \< 10mm, the puncture procedure was continued until the cumulative length of sample's mvc was ≥10mm, and all the sample collected during this process were placed into bottle a and fixed with formalin. in group 2, two needles were used to obtain tissue strips, and all the tissue strips were placed into bottle a formalin. researchers will compare the diagnostic efficacy, core tissue acquisition ability, number of punctures and puncture time between the mose technique and two-needle puncture method.


Eligibility criteria:
inclusion criteria: * (before the trial, subjects must meet all of the requirements listed below in order to be enrolled) 1. 18-80 years old (inclusive), male and female; 2. patients with pancreatic solid mass \> 1cm detected by ct/mri/pet-ct or eus and requiring eus-fnb diagnosis. 3. written informed consent was obtained; exclusion criteria: * (before the trial, participants could not be enrolled if they met any of the following requirements) 1. contraindications to endoscopy, such as severe cardiovascular and cerebrovascular diseases; 2. bleeding coagulation dysfunction (prothrombin international normalized ratio ≥1.5, platelet count ≤ 50 000) or use of antiplatelet drugs; 3. confirmed pregnancy or possible pregnancy; 4. pathological diagnosis has been obtained by other methods; 5. refuse to participate in the study, are participating in another observational clinical trial, or have participated in another clinical trial within 60 days. 6. other situations where eus-fnb could not be performed.

Keywords: eus-fnb solid pancreatic lesion sample processing 22d franseen needle
a study of different formulations of the l-ppds in subjects with oh or oag

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the latanoprost-ppds in subjects with ocular hypertension or open-angle glaucoma.


Eligibility criteria:
inclusion criteria: * subjects over 18 years of age diagnosed with ocular hypertension or open-angle glaucoma * subjects who have a best corrected visual acuity of 20/100 or better exclusion criteria: * subjects who wear contact lenses * subjects who have uncontrolled medical conditions * subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic ocular topical medications * subjects who have a history of chronic or recurrent inflammatory eye disease
phase 1 study of mpc-6827 and temozolomide in metastatic melanoma

Conditions: Metastatic Melanoma

Summary: this is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. three dose levels of mpc-6827 will be administered with temozolomide to three separate cohorts. study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity of mpc-6827 when given with temozolomide.


Eligibility criteria:
inclusion criteria: * histologically proven melanoma * for subjects with brain metastases that require radiation, therapy must have been completed at least 4 weeks prior to day 1 of study drug * have unresectable melanoma with measurable metastases * be a minimum of 4 weeks since prior surgical resection or major surgical procedure and a minimum of 2 weeks since chemotherapy/ biochemotherapy * performance score of karnofsky ≥ 60%, or eastern cooperative oncology group (ecog) ≤ 2, or who ≤ 2 * if steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week exclusion criteria: * hypersensitivity to cremophor el * have current/active intratumor hemorrhage by ct/mri within 3 weeks prior to day 1 of study drug confirmed by ct/mri * have ocular melanoma * have primary intradural melanoma or leptomeningeal involvement * have cardiovascular disease (unstable angina or mi) * have cerebrovascular disease (stroke and/or tia) * have uncontrolled hypertension * have a cardiac ejection fraction \< 50% * have troponin-i elevated above the normal range

Keywords: melanoma metastatic
local vibration in cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: the aim of this study is to evaluate the effect of local vibration application on the upper extremity pain, paresthesia, neck pain, and limitations in cervical joint range of motion experienced by patients with cervical radiculopathy.

at least 34 patients diagnosed with cervical radiculopathy who meet the inclusion and exclusion criteria will be included in the study. subsequently, the patients will be randomly divided into two groups. patients in the first group will receive placebo local vibration application in addition to conventional treatment, while patients in the second group will receive local vibration application in addition to conventional treatment

Eligibility criteria:
inclusion criteria: * 1. between the ages of 18 and 70, * 2. nerve root compression according to the magnetic resonance imaging, * 3. unilateral or bilateral neck pain rated 3 or higher on the numeric pain rating scale, or neck pain with paresthesia or upper extremity pain rated 3 or higher on the numeric pain rating scale. exclusion criteria: * 1. history of previous cervical or thoracic spinal surgery, * 2. symptoms or signs of upper motor neuron disorder, * 3. body mass index (bmi) higher than 35 kg/m2, * 4. having received spinal injection in the last two weeks, * 5. presence of local infection at the application site, * 6. upper extremity nerve entrapment syndrome (such as carpal tunnel or cubital tunnel syndrome), * 7. diagnosis of systemic inflammatory arthritis (such as rheumatoid arthritis, etc.), * 8. having engaged in strenuous exercise in the last 24 hours, * 9. poor or noncompliance to the treatment program

Keywords: neck pain paresthesia
hipec, intravenous chemotherapy and surgery for the treatment of advanced gc with peritoneal metastasis

Conditions: Gastric Cancer

Summary: explore the hyperthermic intraperitoneal chemotherapy (hipec) and intravenous chemotherapy for creating the operation chance in advanced gastric cancer with peritoneal metastasis.

to assess the effectiveness and safety of hyperthermic intraperitoneal chemotherapy, intravenous chemotherapy combined with surgery for the treatment of advanced gastric cancer with peritoneal metastasis,so as to further find out the optimal protocol for the conversion therapy in the patients with advanced gastric cancer.

Eligibility criteria:
inclusion criteria: gastric cancer confirmed by endoscopic biopsy , and enhanced ct suspected to have peritoneal metastasis, including ascites, ovarian metastasis, omentum or peritoneal metastasis. * definitely diagnosed as above stage of stomach cancer before the operation via ct or mri, ultrasonic endoscopy and blood tumor antigen test, or through the laparoscopy if necessary * untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy) * ecog (eastern cooperative oncology group) : 0\~2 * age: 18\~75 years old * normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). for example: wbc\>4.0×109/l, neu \>1.5×109/l, plt\>100×109/l, bil\<1.5 times of upper limit of normal reference value, alt and ast\<2.5 times of upper limit of normal reference value, and cre\<1.2mg/dl * good cardiac function before the recruitment, no seizure of myocardial infarction in past half year, and controllable hypertension and other coronary heart diseases * not concomitant with other uncontrollable benign diseases before the recruitment (e.g. the infection in the lung, kidney and liver) * not participating in other study projects before and during the treatment * signed the informed consent form exclusion criteria: * not conforming to above inclusion criteria * distal metastasis to lung, liver, or para aortic lymph node metastasis * ever operation on the stomach * operation intolerance due to other systemic basic diseases * ever administered other drugs (including tcm drugs) before the recruitment, or no guarantee of progress according to the study requirement after the recruitment * allergy to the drugs in this protocol * pregnant or lactating women * women at childbearing age and of pregnancy desire during the study

Keywords: chemotherapy surgery surgically-created resection cavity adverse reaction to drug
assessment of the effect of a dermatology-oriented spa therapy on the quality of life of patients with psoriasis

Conditions: Psoriasis

Summary: evaluation of the effect of a dermatology-oriented spa therapy at 4.5 months on the quality of life of patients suffering from psoriasis

bareges is a: prospective, before/after, cohort follow-up study with repeated measurements monocentric study with the dispensation of a 3-week dermatolgy-oriented spa therapy in barèges

Eligibility criteria:
inclusion criteria: * age ≥ 18 years patient with psoriasis stable treatment in the last 6 months. dlqi \> 10 patient presenting an indication for thermal treatment focused on dermatology (possible dual orientation). patient affiliated to the social security system or such a system available for an 18-day spa treatment and a 9-month follow-up for women of childbearing age: effective contraception patient information and informed consent signature exclusion criteria: contraindication to thermal treatment (e.g., ongoing chemotherapy/radiotherapy, uncontrolled progressive neoplasia, progressive heart disease, etc., according to the investigator's assessment) predictable intolerance to thermal treatments (intolerance to heat, baths, etc.) patient who has already undergone a dermatology-oriented spa treatment within the current thermal season subject already included in an interventional clinical research protocol persons referred to in articles l1121-5 to l1121-8 of the "code de la santé publique" (pregnant women, women in labour and parturient and nursing mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure or not being able to verbally communicate their agreement, minor)

Keywords: psoriasis spa therapy
the purpose of this study is to determine whether topical application of pep005 is safe for the treatment of common wart(s)

Conditions: Warts

Summary: verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (hpv). common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact). common warts have a characteristic cauliflower-like surface, are typically slightly raised above the surrounding skin and are generally diagnosed by visual inspection.the treatment of warts poses a therapeutic challenge for physicians. no single therapy has been proven effective at achieving complete remission in every patient.this study will aim to evaluate an up-to a three-day course of therapy with 0.05% pep005 topical gel.


Eligibility criteria:
inclusion criteria: * male and female patients at least 18 years of age. * a clinically diagnosed, single common cutaneous viral wart (verruca vulgaris) on the dorsal hand. * written informed consent has been obtained. * agreement from the patient to allow photographs of the common wart(s) treatment area to be taken and used as part of the study package.

Keywords: pep005 common wart(s) common warts (verruca[e] vulgaris)
validation of the pecarn clinical decision rule for children with minor head trauma

Conditions: Head Injury

Summary: to date, the pediatric emergency care applied research network (pecarn) rule for identifying children who are at very low risk of clinically-important traumatic brain injuries after minor head trauma has not been validated prospectively in an independent population. our goal was to evaluate the diagnostic performance of the pecarn clinical decision rule in a french pediatric population in multiple clinical settings.

head injury is a frequent reason for consultation with pediatric emergencies, over 95% are mild head injury defined by a glasgow score greater than or equal to 13. in october 2009, the pediatric emergency care applied research network has published a rule clinical decision support of mild head injury of the child with the aim to identify children at very low risk for clinically severe intracranial lesions in order to avoid the use of ct and unnecessary exposure to radiation ionizing. this clinical decision rule constructed from a multicenter prospective cohort 42,412 american children allows on anamnestic and clinical elements to guide medical decision for conducting brain imaging, hospital monitoring or discharge home placing the child in three levels of risk of clinically severe intracranial lesions. since march 2012, the french emergency medicine society recommends for the treatment of mild head trauma the child's use of the clinical decision rule provided that it is the subject of a validation study externally. indeed, after the construction phase and before its daily application, a clinical decision rule must be subject to an broad validation process so that its predictive performance can be definitively established. the investigators' work aims to conduct this broad validation study prospective multicenter way in a french pediatric population, as recommended by the french emergency medicine society, in order to confirm or deny its predictive performance and allow its application and generalization. the investigators will check and if the clinical decision rule is adapted or not to the management of mild head injuries in the french pediatric population.

Eligibility criteria:
inclusion criteria: * children under 16 years admitted to an emergency room for mild head injury (glasgow coma scale score ≥14) in the previous 24 hours * children who have agreed to participate in the study (if age\> 8 years) * patient parents have accepted the participation of their child in the study exclusion criteria: * children with bleeding disorders * ventricular shunt presence * benin mechanism of trauma (fall of the height of the child or impact against an object while walking / running with no sign that the scalp dermabrasion) * penetrating trauma * known brain tumor * previously known neurological disorders * evaluation scanographic in another hospital before emergency review

Keywords: minor head trauma children clinical decision rule